143. R. J. Brentjens et al., Safety and persistence of adoptively
transferred autologous CD19-targeted T cells in patients with
relapsed or chemotherapy refractory B-cell leukemias. Blood
118, 4817–4828 (2011). doi: 10.1182/blood-2011-04-348540;
144. R. J. Brentjens et al., CD19-targeted T cells rapidly induce
molecular remissions in adults with chemotherapy-refractory
acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38
(2013). doi: 10.1126/scitranslmed.3005930; pmid: 23515080
145. S. L. Maude et al., Chimeric antigen receptor T cells for sustained
remissions in leukemia. N. Engl. J. Med. 371, 1507–1517
(2014). doi: 10.1056/NEJMoa1407222; pmid: 25317870
146. D. W. Lee et al., T cells expressing CD19 chimeric antigen
receptors for acute lymphoblastic leukaemia in children and
young adults: A phase 1 dose-escalation trial. Lancet 385,
517–528 (2015). doi: 10.1016/S0140-6736(14)61403-3;
147. J. N. Kochenderfer et al., Chemotherapy-refractory diffuse
large B-cell lymphoma and indolent B-cell malignancies can
be effectively treated with autologous T cells expressing an
anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549
(2015). doi: 10.1200/JCO.2014.56.2025; pmid: 25154820
148. C. J. Turtle et al., Immunotherapy of non-Hodgkin’s
lymphoma with a defined ratio of CD8+ and CD4+ CD19-
specific chimeric antigen receptor-modified T cells. Sci.
Transl. Med. 8, 355ra116 (2016). doi: 10.1126/scitranslmed.
aaf8621; pmid: 27605551
149. D. L. Porter, B. L. Levine, M. Kalos, A. Bagg, C. H. June,
Chimeric antigen receptor-modified T cells in chronic
lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
doi: 10.1056/NEJMoa1103849; pmid: 21830940
150. J. N. Kochenderfer et al., Eradication of B-lineage cells and
regression of lymphoma in a patient treated with autologous
T cells genetically engineered to recognize CD19. Blood 116,
4099–4102 (2010). doi: 10.1182/blood-2010-04-281931;
151. P. F. Robbins et al., Tumor regression in patients with
metastatic synovial cell sarcoma and melanoma using
genetically engineered lymphocytes reactive with NY-ESO-1.
J. Clin. Oncol. 29, 917–924 (2011). doi: 10.1200/
JCO.2010.32.2537; pmid: 21282551
152. S. Hacein-Bey Abina et al., Outcomes following gene therapy
in patients with severe Wiskott-Aldrich syndrome. JAMA
313, 1550–1563 (2015). doi: 10.1001/jama.2015.3253;
153. S. S. De Ravin et al., Lentiviral hematopoietic stem cell gene
therapy for X-linked severe combined immunodeficiency. Sci.
Transl. Med. 8, 335ra57 (2016). doi: 10.1126/scitranslmed.
aad8856; pmid: 27099176
154. M. Sessa et al., Lentiviral haemopoietic stem-cell gene
therapy in early-onset metachromatic leukodystrophy: An ad-
hoc analysis of a non-randomised, open-label, phase 1/2 trial.
Lancet 388, 476–487 (2016). doi: 10.1016/S0140-6736(16)
30374-9; pmid: 27289174
155. D. Gaudet et al., Efficacy and long-term safety of
alipogene tiparvovec (AAV1-LPLS447X) gene therapy for
lipoprotein lipase deficiency: An open-label trial. Gene Ther.
20, 361–369 (2013). doi: 10.1038/gt.2012.43; pmid: 22717743
K.A.H. is President and Head of Research and Development at Spark
Therapeutics, a biotechnology company involved in discovering,
developing, and delivering AAV gene therapies for genetic diseases.
K.O. has a sponsored research agreement with Takara Bio for CAR-T
gene therapy. J.K.J. is a paid scientific adviser for Beam
Therapeutics, Editas Medicine, and Pairwise Plants and holds equity
in Beam Therapeutics, Editas Medicine, Monitor Biotechnologies,
Pairwise Plants, Poseida Therapeutics, and Transposagen
Biopharmaceuticals. These financial interests were reviewed and
are managed by Massachusetts General Hospital and Partners
HealthCare in accordance with their conflict of interest policies.
J.K.J. has sponsored research agreements with AstraZeneca and
Takeda Pharmaceuticals and is an inventor on patent applications
and issued patents that cover genome editing technologies.
D.B.K. is on the Scientific Advisory Boards of Orchard Therapeutics
and Kite Pharma, companies developing gene therapies, and
has a Sponsored Research Agreement from BioMarin Pharmaceutical
on lentiviral vectors for sickle cell disease. D.B.K. is an inventor
on intellectual property licensed to Orchard Therapeutics from
the University of California Los Angeles, on lentiviral vector gene
therapy for adenosine deaminase–deficient SCID. M.S. has
sponsored research agreements with Juno Therapeutics and
Fate Therapeutics. M.S. is an inventor on patents related to
CAR therapies that are licensed by Memorial Sloan-Kettering
Dunbar et al., Science 359, eaan4672 (2018) 12 January 2018 10 of 10